SEOUL, South Korea (AP) — South Korea's top financial regulator said Thursday it had found intentional breaches of accounting rules at Samsung Biologics, the contract drugmaking unit once seen as Samsung's future growth engine. The Financial Services Commission said it will bring the case to...